307 related articles for article (PubMed ID: 17185414)
1. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.
Galkin AV; Melnick JS; Kim S; Hood TL; Li N; Li L; Xia G; Steensma R; Chopiuk G; Jiang J; Wan Y; Ding P; Liu Y; Sun F; Schultz PG; Gray NS; Warmuth M
Proc Natl Acad Sci U S A; 2007 Jan; 104(1):270-5. PubMed ID: 17185414
[TBL] [Abstract][Full Text] [Related]
2. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini P; Gastaldi T; Falini B; Rosolen A
Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
[TBL] [Abstract][Full Text] [Related]
3. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
Hsu FY; Johnston PB; Burke KA; Zhao Y
Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro.
Hsu FY; Zhao Y; Anderson WF; Johnston PB
Cancer Invest; 2007 Jun; 25(4):240-8. PubMed ID: 17612934
[TBL] [Abstract][Full Text] [Related]
5. Model of inhibition of the NPM-ALK kinase activity by herbimycin A.
Turturro F; Arnold MD; Frist AY; Pulford K
Clin Cancer Res; 2002 Jan; 8(1):240-5. PubMed ID: 11801565
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma.
Amin HM; McDonnell TJ; Ma Y; Lin Q; Fujio Y; Kunisada K; Leventaki V; Das P; Rassidakis GZ; Cutler C; Medeiros LJ; Lai R
Oncogene; 2004 Jul; 23(32):5426-34. PubMed ID: 15184887
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
[TBL] [Abstract][Full Text] [Related]
8. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
Ceccon M; Mologni L; Bisson W; Scapozza L; Gambacorti-Passerini C
Mol Cancer Res; 2013 Feb; 11(2):122-32. PubMed ID: 23239810
[TBL] [Abstract][Full Text] [Related]
9. Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.
Nieborowska-Skorska M; Slupianek A; Xue L; Zhang Q; Raghunath PN; Hoser G; Wasik MA; Morris SW; Skorski T
Cancer Res; 2001 Sep; 61(17):6517-23. PubMed ID: 11522649
[TBL] [Abstract][Full Text] [Related]
10. Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Lai R; Rassidakis GZ; Medeiros LJ; Ramdas L; Goy AH; Cutler C; Fujio Y; Kunisada K; Amin HM; Gilles F
Am J Pathol; 2004 Jun; 164(6):2251-8. PubMed ID: 15161657
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
12. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.
Wasik MA; Zhang Q; Marzec M; Kasprzycka M; Wang HY; Liu X
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S27-35. PubMed ID: 19393833
[TBL] [Abstract][Full Text] [Related]
14. NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma.
Leventaki V; Drakos E; Medeiros LJ; Lim MS; Elenitoba-Johnson KS; Claret FX; Rassidakis GZ
Blood; 2007 Sep; 110(5):1621-30. PubMed ID: 17416736
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein.
Ergin M; Denning MF; Izban KF; Amin HM; Martinez RL; Saeed S; Alkan S
Exp Hematol; 2001 Sep; 29(9):1082-90. PubMed ID: 11532349
[TBL] [Abstract][Full Text] [Related]
16. ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors.
Lu L; Ghose AK; Quail MR; Albom MS; Durkin JT; Holskin BP; Angeles TS; Meyer SL; Ruggeri BA; Cheng M
Biochemistry; 2009 Apr; 48(16):3600-9. PubMed ID: 19249873
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.
Cerchietti L; Damm-Welk C; Vater I; Klapper W; Harder L; Pott C; Yang SN; Reiter A; Siebert R; Melnick A; Woessmann W
PLoS One; 2011 Apr; 6(4):e18436. PubMed ID: 21494621
[TBL] [Abstract][Full Text] [Related]
18. A simple, highly visual in vivo screen for anaplastic lymphoma kinase inhibitors.
Rodrigues FS; Yang X; Nikaido M; Liu Q; Kelsh RN
ACS Chem Biol; 2012 Dec; 7(12):1968-74. PubMed ID: 22985331
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel crosstalk between casein kinase 2α and NPM-ALK in ALK-positive anaplastic large cell lymphoma.
Armanious H; Gelebart P; Anand M; Lai R
Cell Signal; 2013 Feb; 25(2):381-8. PubMed ID: 23153582
[TBL] [Abstract][Full Text] [Related]
20. The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation.
Hübinger G; Scheffrahn I; Müller E; Bai R; Duyster J; Morris SW; Schrezenmeier H; Bergmann L
Exp Hematol; 1999 Dec; 27(12):1796-805. PubMed ID: 10641597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
